355 related articles for article (PubMed ID: 21876620)
1. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Long J; Qu T; Pan XF; Tang X; Wan HH; Qiu P; Xu YH
J Cancer Res Ther; 2018 Dec; 14(Supplement):S1188-S1192. PubMed ID: 30539869
[TBL] [Abstract][Full Text] [Related]
6. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
9. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.
Zeng Z; Shi F; Zhou L; Zhang MN; Chen Y; Chang XJ; Lu YY; Bai WL; Qu JH; Wang CP; Wang H; Lou M; Wang FS; Lv JY; Yang YP
PLoS One; 2011; 6(9):e23621. PubMed ID: 21912640
[TBL] [Abstract][Full Text] [Related]
11. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.
Zhang E; Zhang X; Liu J; Wang B; Tian Y; Kosinska AD; Ma Z; Xu Y; Dittmer U; Roggendorf M; Yang D; Lu M
PLoS One; 2011; 6(10):e26196. PubMed ID: 22022563
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
14. [Increased expressions of programmed death 1 (PD-1) and its ligands in peripheral CD3(+) T cells and CD19(+) B cells in patients with hepatocellular carcinoma].
Liu W; Chai L; Liang J; Lu Z; Yang S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1243-7. PubMed ID: 27609582
[TBL] [Abstract][Full Text] [Related]
15. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
16. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.
Saha A; Aoyama K; Taylor PA; Koehn BH; Veenstra RG; Panoskaltsis-Mortari A; Munn DH; Murphy WJ; Azuma M; Yagita H; Fife BT; Sayegh MH; Najafian N; Socie G; Ahmed R; Freeman GJ; Sharpe AH; Blazar BR
Blood; 2013 Oct; 122(17):3062-73. PubMed ID: 24030385
[TBL] [Abstract][Full Text] [Related]
17. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Dynamics of Programmed Death Ligand-1 Expression on Circulating CD14
Huang ZY; Xu P; Li JH; Zeng CH; Song HF; Chen H; Zhu YB; Song YY; Lu HL; Shen CP; Zhang XG; Wu MY; Wang XF
Viral Immunol; 2017 Apr; 30(3):224-231. PubMed ID: 28005469
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Yarchoan M; Xing D; Luan L; Xu H; Sharma RB; Popovic A; Pawlik TM; Kim AK; Zhu Q; Jaffee EM; Taube JM; Anders RA
Clin Cancer Res; 2017 Dec; 23(23):7333-7339. PubMed ID: 28928158
[No Abstract] [Full Text] [Related]
20. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
